Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CAR-T Cell Therapy Shows Lasting Results in Two Pediatric Patients



While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

Share this!

January 27, 2017 | by Sarah Hand, M.Sc.

Two pediatric patients with leukemia have been in remission for over a year after receiving experimental CAR-T cell therapy. While Cellectis’ immunotherapy agent is now being tested in clinical trials involving both children and adult patients, the two infant girls were the first to receive the treatment back in 2015.

The two girls – 11-months-old and 16-months-old at the time of treatment – are both doing well over a year after receiving the modified CAR-T cells. The doctors at Great Ormond Street Institute of Child Health, University College London, who administered the experimental treatment have now presented the case studies in an article published in the journal, Science Translational Medicine.

The cases involved the use of so-called “off-the-shelf” CAR-T cells to target cancer cells. CAR-T cell therapy normally involves gene editing a patient’s own immune cells to allow them to destroy tumor tissue.

While this approach has been shown to be relatively safe and effective, it requires an expensive and laborious procedure of collecting enough immune cells from the patient to be edited. If a patient is very young or very sick, the number of viable immune cells may be limited.

If a patient were to be infused with off-the-shelf cells which are not their own, it’s likely that the foreign cells would attack their body in a phenomenon known as graft-versus-host disease. To combat this response, pharmaceutical company Cellectis developed a gene editing tool to turn off the gene, called TCRαβ, responsible for allowing the donor cells to attack the host.

Cellectis’ gene editing tool allowed for the creation of UCART19 cells which could be universally accepted by patients with B-cell acute lymphoblastic leukemia. However, because the gene editing tool is not 100 percent accurate, both pediatric patients treated with the UCART19 cells developed some signs of graft-versus-host disease.

A gene editing technique known as TALEN was used by Cellectis to silence TCRαβ, however researchers are now looking to CRISPR for an easier and less-expensive gene editing tool. CRISPR-edited cells are now being assessed in two cancer clinical trials taking place in the US and China.

Keywords: CAR-T, Gene Editing, Leukemia


Share this with your colleagues!

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News

FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News

New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

High Performance Computing for High Content Screening - A Case Study

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Treatment of Psoriasis: Improvements Through Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.